News Releases

Keyword Search

Sep-07-2023
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
Aug-10-2023
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
Aug-03-2023
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
Aug-03-2023
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
Jun-30-2023
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Jun-06-2023
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma
May-31-2023
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
May-04-2023
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
Apr-27-2023
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
Apr-13-2023
Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors